10,871 Shares in Haleon plc (NYSE:HLN) Bought by Atala Financial Inc

Atala Financial Inc bought a new position in Haleon plc (NYSE:HLN) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,871 shares of the company’s stock, valued at approximately $104,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC lifted its position in Haleon by 5.8% in the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after purchasing an additional 5,768,117 shares during the period. Wellington Management Group LLP lifted its position in Haleon by 49.9% in the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after purchasing an additional 3,046,841 shares during the period. Douglas Lane & Associates LLC lifted its position in Haleon by 1.9% in the fourth quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company’s stock worth $82,274,000 after purchasing an additional 161,865 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Haleon by 25.3% during the third quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock valued at $53,791,000 after acquiring an additional 1,026,939 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Haleon during the fourth quarter valued at $42,193,000. 6.67% of the stock is owned by institutional investors.

Haleon Price Performance

Shares of HLN stock opened at $10.16 on Friday. The stock has a 50-day moving average price of $9.74 and a 200 day moving average price of $9.87. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a market cap of $45.97 billion, a price-to-earnings ratio of 29.87, a PEG ratio of 2.82 and a beta of 0.25. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80.

Haleon (NYSE:HLN) last issued its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The firm had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Research analysts expect that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The firm also recently disclosed a — dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be issued a dividend of $0.1166 per share. This represents a dividend yield of 1.6%. The ex-dividend date is Friday, April 25th. This is a boost from Haleon’s previous — dividend of $0.05. Haleon’s payout ratio is 58.97%.

Wall Street Analysts Forecast Growth

HLN has been the subject of a number of analyst reports. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a report on Monday, March 3rd. HSBC reissued a “hold” rating on shares of Haleon in a report on Wednesday, March 5th. Hsbc Global Res lowered Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Finally, Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Six equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.